Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
38 results
D1.103 - Two cases of discrepancy between fractional exhaled nitric oxide and airway eosinophils in asthma
D1.104 - Severe Bronchial Asthma Phenotypes in a Referral Tertiary Center in Saudi Arabia
D1.105 - Lichen Planus induced by treatment of severe eosinophilic asthma with biological therapy
D1.106 - Grape polyphenols reduce the concentration of LPS in patients with asthma
D1.107 - Polyphenol concentrate reduces CRP in asthma patients who have had COVID-19
D1.108 - Grape polyphenols increase the concentration of BPI in asthma patients who have had SARS-CoV-2
D1.109 - Predominance of eosinophilic pathogenetic mechanisms in a severe allergic asthma patient on biologic therapy
D1.110 - Analysis of clinical and anamnestic risk factors of bronchial asthma in children
D1.111 - Improving severe asthma through psychological management of traumatic life events
D1.112 - Managing patients with Type 2 inflammation in a joint interdisciplinary “United Airways Clinic” at Lund University Hospital, Sweden
D1.113 - Severe Asthma and Depression: the Overlooked Burden
D1.114 - The Hidden Costs of Severe Asthma Treatment: Unveiling the Iatrogenic Burden
D1.115 - Post-emergency asthma management
- D3.100 - Risk Factors and Biomarkers for COVID-19 and Allergic Diseases
- D3.102 - PROMs Improvement Effects of Biologics in Chronic Rhinosinusitis with Nasal Polyps Patients: Real-life Experience
- D3.103 - Impact of aspirin-induced bronchospasm on the in vitro Aspirin Hypersensitivity Diagnostic Index in the patients with Aspirin Exacerbated Respiratory Disease
- D3.104 - A step towards standardized Clinical Remission Criteria for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): insights from a real-life study
- D3.105 - Suspected EGPA in a patient on Dupilumab treatment: confirmed diagnosis of sarcoidosis - case report
- D3.106 - Real-World Dupilumab Effectiveness Through 18 Months in Patients with CRSwNP and Coexisting Asthma: Results from the Global AROMA Registry
- D3.108 - PTGDR2 Blood Expression as a Potential Biomarker for Predicting Super-Response to IL-5-Targeted Therapies in Severe Asthma
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download